Tango Therapeutics, Inc. 4

Crystal Adam (President, R&D of Tango Therapeutics, Inc.) exercised 27,000 options at $5.20 and sold 27,000 common shares for about $615,000 under a Rule 10b5-1 plan, ending with 115,743 shares owned.

On June 1, 2026, Crystal Adam, President, R&D of Tango Therapeutics, Inc., exercised 27,000 stock options with a $5.20 strike price and received 27,000 shares of common stock, then sold an aggregate 27,000 shares in two open‑market transactions at weighted average prices of $22.252 (6,140 shares) and $23.0558 (20,860 shares), all under a pre-arranged Rule 10b5‑1 trading plan. The gross value of the option exercise was approximately $140,400 at the strike price, while the total proceeds from the sales were about $615,000, implying a realized spread of roughly $475,000 before taxes and commissions. Following these transactions, Adam’s direct ownership decreased modestly from 142,743 to 115,743 shares, which at roughly $22.60 per share is worth about $2.6 million, indicating she retains a substantial equity position despite the liquidity event.

Filing Facts

CIK

1819133

Ticker

TNGX

Form

4

Source Type

sec

Accession

0001193125-26-255940

Alert Tier

6